The verdict
Our read at a glance.
Whether omiganan's antimicrobial-peptide mechanism and its mixed skin and infection trials support its use as a treatment.
- The signal
- Omiganan has been tested in trials for preventing catheter-related infection and for skin conditions such as rosacea, acne, and atopic dermatitis. Results have been mixed, with some early signals but no clear, consistent approval-grade benefit, and it is not approved for any use.
- The unknown
- Whether omiganan can show clear, reliable benefit in a specific condition, and which skin or infection setting, if any, is the right target.
- Our read
- A real topical antimicrobial peptide with a mixed, inconclusive trial record, not a proven treatment. Omiganan's mechanism is genuine and it has been widely studied, but no indication has produced clear, approval-grade benefit, so it remains investigational.
The mechanism
How it works.
Omiganan is a synthetic antimicrobial peptide derived from indolicidin, a short peptide made by cattle immune cells. As a positively charged peptide it binds the negatively charged membranes of bacteria and fungi and disrupts them, killing the microbes directly, and it also appears to dampen local inflammatory signaling. It was applied as a topical gel to reduce microbes at catheter sites and to calm inflammatory skin conditions like rosacea and acne, but its trials across these uses have given mixed results and it is not approved.
Safety & regulatory boundary
The consequential part.
Omiganan is not an approved drug, and its trial results across conditions have been mixed. It was studied only as a topical product under medical supervision. Research-labeled or compounded omiganan is not an approved product, and the antimicrobial-peptide concept does not validate broad infection or skin claims.
What's next
What we're watching.
Whether any omiganan indication reaches a clear positive trial and approval, and in which condition.
Context
Why this is discussed.
Omiganan is another leading test of whether antimicrobial peptides can become approved drugs, studied across infection prevention and several skin conditions.
The evidence base
20 cited references.
Registered trials8
ClinicalTrials.gov · PHASE3 · COMPLETED · 2015-12
ClinicalTrials.gov · PHASE3 · COMPLETED · 2015-10
ClinicalTrials.gov · PHASE3 · COMPLETED · 2015-10
ClinicalTrials.gov · PHASE2 · UNKNOWN · 2018-10-22
ClinicalTrials.gov · PHASE2 · COMPLETED · 2017-03-08
ClinicalTrials.gov · PHASE2 · COMPLETED · 2015-11
ClinicalTrials.gov · PHASE1 · COMPLETED · 2017-02-06
ClinicalTrials.gov · PHASE2 · COMPLETED · 2016-07
Indexed literature (PubMed)12
Cong TX et al. · Arch Dermatol Res · 2019
Isaacson RE · Curr Opin Investig Drugs · 2003
Sader HS et al. · Antimicrob Agents Chemother · 2004
Anderegg TR et al. · J Clin Microbiol · 2004
Septimus EJ et al. · Clin Microbiol Rev · 2016
Melo MN et al. · Recent Pat Antiinfect Drug Discov · 2006
You Y et al. · Amino Acids · 2023
Grievink HW et al. · Clin Transl Sci · 2020
Niemeyer-van der Kolk T et al. · Clin Transl Sci · 2020
Wang S et al. · ACS Biomater Sci Eng · 2024
Fritsche TR et al. · Diagn Microbiol Infect Dis · 2008
Keep reading